PWMG
BMRN icon

Prestige Wealth Management Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Prestige Wealth Management Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95K Hold
34
– – ﹤0.01% 769
2026
Q1 		$1.92K Hold
34
– – ﹤0.01% 748
2025
Q4 		$2.02K Sell
34
-14
-29% -$762 ﹤0.01% 760
2025
Q3 		$2.6K Buy
48
+14
+41% +$801 ﹤0.01% 682
2025
Q2 		$1.87K Sell
34
-42
-55% -$2.47K ﹤0.01% 748
2025
Q1 		$5.37K Buy
76
+42
+124% +$2.83K ﹤0.01% 551
2024
Q4 		$2.23K Sell
34
-25
-42% -$1.68K ﹤0.01% 761
2024
Q3 		$4.15K Buy
59
+25
+74% +$2.09K ﹤0.01% 638
2024
Q2 		$2.8K Sell
34
-18
-35% -$1.5K ﹤0.01% 654
2024
Q1 		$4.54K Sell
52
-64
-55% -$5.73K ﹤0.01% 596
2023
Q4 		$11.2K Buy
116
+6
+5% +$531 ﹤0.01% 428
2023
Q3 		$9.73K Sell
110
-27
-20% -$2.4K ﹤0.01% 445
2023
Q2 		$11.9K Hold
137
– – ﹤0.01% 437
2023
Q1 		$13.3K Buy
137
+7
+5% +$726 ﹤0.01% 391
2022
Q4 		$13.5K Buy
130
+9
+7% +$845 ﹤0.01% 406
2022
Q3 		$11K Sell
121
-100
-45% -$8.9K ﹤0.01% 402
2022
Q2 		$19K Buy
221
+72
+48% +$5.73K 0.01% 335
2022
Q1 		$11K Hold
149
– – ﹤0.01% 438
2021
Q4 		$13K Hold
149
– – ﹤0.01% 438
2021
Q3 		$11K Buy
149
+12
+9% +$947 ﹤0.01% 462
2021
Q2 		$11K Buy
137
+16
+13% +$1.27K ﹤0.01% 451
2021
Q1 		$9K Sell
121
-19
-14% -$1.55K ﹤0.01% 488
2020
Q4 		$12K Buy
140
+73
+109% +$5.79K ﹤0.01% 421
2020
Q3 		$5K Sell
67
-60
-47% -$6.07K ﹤0.01% 531
2020
Q2 		$16K Buy
127
+64
+102% +$6.36K 0.01% 361
2020
Q1 		$5K Buy
+63
New +$5.43K ﹤0.01% 482
2019
Q1 		– Sell
-127
Closed -$11K – 574
2018
Q4 		$11K Buy
+127
New +$12.1K 0.01% 410

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Prestige Wealth Management Group's BMRN Position: Q2 2026 in Review

Prestige Wealth Management Group held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 34 shares worth $1.95K. The position accounts for ﹤0.01% of the portfolio, ranked #769.

Prestige Wealth Management Group first reported a position in BMRN in Q4 2018 and has held it in 27 quarters since. The position peaked at $19K in Q2 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Prestige Wealth Management Group held 34 shares of BioMarin Pharmaceuticals worth $1.95K as of Q2 2026.
  • Prestige Wealth Management Group left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #769 holding.
  • Prestige Wealth Management Group first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 27 quarters since.
  • Prestige Wealth Management Group's BioMarin Pharmaceuticals position peaked at $19K in Q2 2022.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.